Biosyngen Group signs contract of Dalian Sino-Singapore Biotech Hub

At the invitation of Dalian Municipal People's Government, Mr. Frank Wang, Chairman of Biosyngen Group and Dr. Victor Li, CEO of Biosyngen Group attended the 10th Singapore-Liaoning Economic and Trade Council (SLETC) meeting in Shenyang and signed a contract in the development of the Dalian Sino-Singapore Biotech Hub.

Dalian Sino-Singapore Biotech Hub will develop the world's pioneering innovative biomedical technologies and products from countries such as Singapore, Germany, France and China, including immune cell therapy for virus-related tumors (nasopharyngeal carcinoma, gastric cancer, etc.) and lymphoma, gene therapy, as well as the production of key materials (viral vector, mRNA, allogenic cell) for cell therapy, and tumor diagnosis (for bladder cancer, prostate cancer, etc.). The Hub will be developed with the partnership between Biosyngen Group and the Dalian Lv Shun District Government. Strongly supported by Dalian Municipal Government, it is one of the key projects of Dalian's strategic industrial development plan in 2020.

The signing ceremony was witnessed by Mr Tang Yijun, Liaoning Governor, the Co-Chairman of SLETC, and Mr Masagos Zulkifli, Minister for the Environment and Water Resources of Singapore and Co-Chairman of SLETC. 11 projects were signed at the council meeting, of which the planned investment of Dalian Sino-Singapore Biotech Hub is RMB 1.5 billion.

Headquartered in Singapore, BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune cell therapy technologies and products in Asia and China.